Navigation Links
Bioniche Provides a Corporate Update
Date:4/27/2009

BELLEVILLE, ON, April 27 /PRNewswire-FirstCall/ - Bioniche Life Sciences Inc. ("Bioniche"; TSX: BNC), a research-based, technology-driven Canadian biopharmaceutical company, today provided an update on its corporate activities.

One of the near-term objectives of the Company, as reported in previous financial disclosures, is the conclusion of a partnering transaction related to its Mycobacterial Cell Wall-DNA Complex (MCC), formulated as Urocidin(TM), for the intravesical treatment of non-muscle-invasive bladder cancer. While the Company has received significant interest in Urodicin from a number of potential partners, it has not yet finalized a transaction and the timeline for doing so has exceeded management's expectations. Given such delays and the Company's near-term cash needs, the Board of Directors has decided to broaden its fundraising strategies to include possible asset dispositions.

In addition, the Company has amended the maturity date of its existing secured revolving credit facility with Valens U.S. (formerly Laurus Master Funds) to June 30, 2009. Bioniche and Valens agreed to this extension to allow the Company time to identify new banking partner(s) after Valens decided to retrench its activities due to credit market conditions, as well as to allow the Company to execute its near-term corporate objectives. This amendment will replace the previously agreed "on demand" status, with an additional fee applicable at maturity of the facility.

The Company is also expanding internal cost cutting measures introduced during the past two fiscal quarters to help address its near-term liquidity requirements.

The Company expects to release its Fiscal 2009 third quarter financial results on May 6, 2009.

About Bioniche Life Sciences Inc.

Bioniche Life Sciences Inc. is a research-based, technology-driven Canadian biopharmaceutical company focused on the discovery, development, manufacturing, and marketing of proprietary products for human and animal health markets worldwide. The fully-integrated company employs approximately 200 skilled personnel and has three operating divisions: Human Health, Animal Health, and Food Safety. The Company's primary goal has been to develop proprietary cancer therapies supported by revenues from marketed products in human and animal health. Bioniche has been named one of the Top 50 Best Small and Medium-Sized Employers in Canada for 2009. For more information, please visit www.Bioniche.com.

Except for historical information, this news release may contain forward-looking statements that reflect the Company's current expectation regarding future events. These forward-looking statements involve risk and uncertainties, which may cause, but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process, and other risks detailed from time to time in the Company's ongoing quarterly and annual reporting.


'/>"/>
SOURCE Bioniche Life Sciences Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Bioniche Completes Recruitment in First Phase III Clinical Trial with Urocidin(TM)
2. Bioniche Revolving Credit Facility Maturity Date Amended
3. Bioniche Phase II Bladder Cancer Trial Results Published in The Journal of Urology
4. Bioniche Warrants Expiration Date to be Extended
5. Bioniche Reports Fiscal 2009 Second Quarter
6. Bioniche Invited to Participate in Canadian Beef Value Chain Roundtable
7. Bioniche Named One of the Top 50 Best Small and Medium Employers in Canada
8. Bioniche Presents MCC Data at the SIU World Uro-Oncology Update in Santiago, Chile
9. Bioniche Reports Fiscal 2009 First Quarter
10. Bioniche Allows Conversion of Portion of Revolving Credit Facility
11. Bioniche Presents E. coli O157:H7 Vaccine Data to World Buiatrics Congress in Budapest, Hungary
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... June 25, 2016 , ... ... issues and applications at AcademyHealth’s Annual Research Meeting June 26-28, 2016, at the ... several important health care topics including advance care planning, healthcare costs and patient ...
(Date:6/25/2016)... ... , ... The temporary closing of Bruton Memorial Library on June 21 due to a possible ... often overlooked aspect of head lice: the parasite’s ability to live away from a human ... but a necessary one in the event that lice have simply gotten out of control. ...
(Date:6/25/2016)... ... ... First Choice Emergency Room , the largest network of independent freestanding emergency ... its new Mesquite-Samuell Farm facility. , “We are pleased to announce Dr. Ogunleye ... M. Muzzarelli, Executive Medical Director of First Choice Emergency Room. , Dr. Ogunleye ...
(Date:6/25/2016)... Oklahoma City, Oklahoma (PRWEB) , ... June 25, ... ... to helping both athletes and non-athletes recover from injury. Recently, he has implemented ... for the Oklahoma City area —Johnson is one of the first doctors to ...
(Date:6/25/2016)... ... ... Conventional wisdom preaches the benefits of moderation, whether it’s a matter of indulgence ... high can result in disappointment, perhaps even self-loathing. However, those who set the bar ... from PsychTests.com reveals that behind the tendency to set low expectations is ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... 2016 The Academy of Managed Care Pharmacy ... that would allow biopharmaceutical companies to more easily share ... formulary and coverage decisions, a move that addresses the ... The recommendations address restrictions in the sharing ... drug label, a prohibition that hinders decision makers from ...
(Date:6/24/2016)... , June 24, 2016 ... Market by Type (Standard Pen Needles, Safety Pen Needles), ... (Insulin, GLP-1, Growth Hormone), Mode of Purchase (Retail, Non-Retail) ... MarketsandMarkets, This report studies the market for the forecast ... to reach USD 2.81 Billion by 2021 from USD ...
(Date:6/23/2016)... 2016  MedSource announced today that it has ... solution of choice.  This latest decision demonstrates MedSource,s ... their clients by offering a state-of-the-art electronic data ... nowEDC as the EDC platform of choice in ... "nowEDC has long been a preferred EDC platform ...
Breaking Medicine Technology: